Publication: Colistin dosing regimens against pseudomonas aeruginosa in critically ill patients: An application of monte carlo simulation
Issued Date
2021-05-01
Resource Type
ISSN
20796382
Other identifier(s)
2-s2.0-85106940473
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Antibiotics. Vol.10, No.5 (2021)
Suggested Citation
Van Thi Khanh Nguyen, Preecha Montakantikul, Pramote Tragulpiankit, Jantana Houngsaitong, Mohd Fazli Shuib Colistin dosing regimens against pseudomonas aeruginosa in critically ill patients: An application of monte carlo simulation. Antibiotics. Vol.10, No.5 (2021). doi:10.3390/antibiotics10050595 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/76186
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Colistin dosing regimens against pseudomonas aeruginosa in critically ill patients: An application of monte carlo simulation
Other Contributor(s)
Abstract
Our aims are to assess various colistin dosing regimens against Pseudomonas aeruginosa (P. aeruginosa) infection in critically ill patients and to propose an appropriate regimen based on microbiological data. A Monte Carlo simulation was performed using the published colistin’s pharmacokinetic parameters of critically ill patients, the published pharmacodynamic target from a mouse thigh infection model, and the minimum inhibitory concentration (MIC) results from a Vietnamese hospital. The probability of target attainment (PTA) of 80% and cumulative fraction of response (CFR) of 90% were used to evaluate the efficacy of each regimen. Of 121 P. aeruginosa laboratory datasets, the carbapenem-resistant P. aeruginosa (CRPA) and the colistin-resistant P. aeruginosa rates were 29.8% and 0.8%, respectively. MIC50,90 were both 0.5 mg/L. The simulated results showed that at MIC of 2 mg/L, most regimens could not reach the PTA target, particularly in patients with normal renal function (Creatinine clearance (CrCl) ≥ 80 mL/min). At MIC of 0.5 mg/L and 1 mg/L, current recommendations still worked well. On the basis of these results, aside from lung infection, our study recommends three regimens against P. aeruginosa infection at MIC of 0.5 mg/L, 1 mg/L, and 2 mg/L. In conclusion, higher total daily doses and fractionated colistin dosing regimens could be the strategy for difficult-to-acquire PTA cases, while a less aggressive dose might be appropriate for empirical treatment in settings with low MIC50/90 .